We would love to hear your thoughts about our site and services, please take our survey here.
The places are taken get ready for next RNS lol x
Frankenstein….it’s alive
CTA application to MHRA and Corporate Update
Thu, 28th Jul 2022 07:00
RNS Number : 9953T
Sareum Holdings PLC
28 July 2022
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
á Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory Agency
á Sareum has made significant progress advancing SDC-1801 towards clinical development and plans to initiate Phase 1 clinical trials in 2022, with a study in psoriasis targeted for 2023
á The Company continues to progress translational studies to support its cancer immunotherapy candidate, SDC-1802
á New EU patent granted (April 2022), protecting the SDC-1802 molecule and pharmaceutical preparations as a therapeutic to treat T-cell acute lymphoblastic leukaemia
á Sareum had a cash position of approximately £4.3 million as at 30 June 2022
á A presentation to investors will take place on 4 August 2022 at 10.00am via the Investor Meet Company platform. See below for registration details.
Cambridge, UK, 28 July 2022 Ð Sareum Holdings plc (AIM: SAR), the specialist drug development company, today announces that it has submitted an application for a Clinical Trial Authorisation ("CTA") to the UK Medicines and Healthcare Products Regulatory Agency ("MHRA") for the development of SDC-1801 as a potential new therapeutic for a range of autoimmune diseases with a focus on psoriasis.
Sareum also provides a broader update on operational activities and pipeline progress.
Hopefully by the AGM that historically has been in December the trials and investment or licence will be well underway with the share price reflecting the value of such monumental achievements..
l personally don’t want there to be an AGM as HOPEFULLY all this will be passed on to a bigger pharmaceutical company for the right price of course ASAP so the products that Tim and John have created can reach there potential faster then we. And of course reinvest my money in the local hairdressers as the Raging bull style ride of AIM is no good for my ticker GLA.. come on sar!
IMHO the RNS 737 update was designed to spook the market and private investors whom hold a lot of SAR stock. It was the last ditch attempt to lower the share price. Question??? was that 76000 share trade a sell that dropped it initially?? Everyone knows 1801 is going to clinic and SAR need investment. This drop was designed to benefit institutional investors, a licence or a buyout???? Everything from here is uphill obviously 737 was returned but as a phase 2 complete drug .. trials stated in SARS pipeline chart.. Anyway BUYOUT, LICENCE OR INVESTMENT inbound only positive news from here. I’m an investor so only going to be positive
IMHO the RNS 737 update was designed to spook the market and private investors whom hold a lot of SAR stock. It was the last ditch attempt to lower the share price. Question??? was that 76000 share trade a sell that dropped it initially?? Everyone knows 1801 is going to clinic and SAR need investment. This drop was designed to benefit institutional investors, a licence or a buyout???? Everything from here is uphill obviously 737 was returned but as a phase 2 complete drug .. trials stated in SARS pipeline chart.. Anyway BUYOUT, LICENCE OR INVESTMENT inbound only positive news from here. I’m an investor so only going to be positive
I posted last about 1801 had moved into the clinical section of the pipeline chart. Dividing line between pre and clinical has gone so not clear on progress probably want to keep price down as PIs not in favour???
Another observation that obviously occurs on other stocks I hold is there are no RNSs referring to holdings in the company weather poss or neg?? Obviously the odd one with accumulating value would be seen as a positive? What the blue blazes has PEEL HUNT been up to??? clarity surely is needed now
Positive news on 1801 CTA and funding in the coming days/weeks will lighten the confusion of yesterdays RNS. Or Is there grounds to call an EGM because it’s all become a little misty to me.
Snippet from 28 July RNS
TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis. Psoriasis is an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments worth more than US$30 billion. Sareum believes that TYK2/JAK1 inhibition offers potential for increased efficacy in psoriasis, compared with existing approved therapies.
Gunner… bidding war springs to mind… bring it on gla
Yep
Just looked on sareums website pipeline … Proprietary programmes chart tells of 1801 has entered clinical stage.. gla
Well it must be a Mount Everest size price of news?????
RNS from GSK last year was 27th Oct 2021 12:00 pm RNS 3rd Quarter Results… Hopefully the long awaited update for progressing our 737 will headline?? Not long now gla
The BOD already know the outcome of the application, how long to RNS
Assessment of your submission
The initial combined review assessment will be completed within 30 days of being submitted. Applications for healthy volunteer trials and sponsor-determined phase I trials in non-oncology patients may qualify for a shortened assessment time and MHRA will work with the research ethics committee to endeavour to expedite these applications. You should state on your covering letter if you think your trial is eligible. Note that trial designs that stretch to investigating the benefit of the treatment to participants may not be eligible for the expedited assessment timeframe.
We will tell you the outcome of your submission along with the outcome of the research ethics committee review, via the combined review process, which could be:
acceptance of the request for a clinical trial authorisation
acceptance of the request for a clinical trial authorisation subject to conditions
grounds for non-acceptance of the request for a clinical trial authorisation
If we raise grounds for non-acceptance you will have the opportunity to respond, usually within 14 days; however this may be extended on request.
Communication informing the applicant of the MHRA and ethics committee decision following receipt of the responses will usually be sent within 60 days of us receiving the original valid application. If an extension to the response date has been agreed this will impact the final decision timeline.
Hopefully the share price will wake up also!!???
Thu, 28th Jul 2022 07:00
RNS Number : 9953T
Sareum Holdings PLC
28 July 2022
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
á Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory Agency
á Sareum has made significant progress advancing SDC-1801 towards clinical development and plans to initiate Phase 1 clinical trials in 2022, with a study in psoriasis targeted for 2023
I suppose something would be better than nothing. Personally I don’t invest in fossil fuel so any indication in that I’m gone no matter the money. GLA
Better to RTO a green energy company into this me thinks. Hopefully something soon on the direction it will take??